: The report's most practical contribution is its guidance on developing robust and scientifically sound LER hold-time studies. The core principle is stated clearly: "The effect of hold time on endotoxin recovery should be assessed by spiking a known amount of endotoxin into undiluted drug substance and drug product and then testing for recoverable endotoxin over time" . Detailed guidance covers endotoxin source selection, spiking procedures, storage containers, holding temperatures, and analytical methods.
The report serves as a comprehensive resource for manufacturers to understand and mitigate LER through several key pillars:
For those needing to perform these specialized studies, laboratories like Microcoat and bioMérieux offer dedicated based on TR 82 guidelines. Technical Report No. 82 "Low Endotoxin Recovery" pda technical report 82
Introducing specific modulators, bovine serum albumin (BSA), or localized dispersing agents to disrupt surfactant binding.
Incubations must mirror actual manufacturing conditions. Samples are stored across several time intervals at (e.g., controlled room temperature or refrigerated storage). Container materials (glass vs. plastic) must also mirror real-world conditions to account for potential surface adsorption effects. 4. Mitigation and Demasking Strategies : The report's most practical contribution is its
Monitoring how endotoxin activity decreases over time when in contact with the drug product.
Companies like Psion , Apple , USRobotics (Palm), or HP might have used “TR-82” internally. The report serves as a comprehensive resource for
The measurement of solid content typically involves techniques such as:
This is where PDA TR 82 has become indispensable. It provides the industry-accepted standard for how to design, execute, and interpret these regulatory-required studies. The European Medicines Agency (EMA) also recognized TR 82 as a relevant standard for designing LER studies in its revised 2025 "Questions and Answers for Biological Medicinal Products". Consequently, global health authorities now widely reference PDA TR 82, making it a key document for any drug developer seeking regulatory approval.
. Here is what you need to know about this essential guidance. What is Low Endotoxin Recovery (LER)?